Neurocrine Biosciences, Inc. (NBIX) AI Stock Analysis

Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for neurological, endocrine, and psychiatric disorders. Its commercial portfolio features INGREZZA, a VMAT2 inhibitor for tardive dyskinesia, alongside ONGENTYS for Parkinson's disease. The company also provides ORILISSA for endometriosis pain and ORIAHNN for heavy menstrual bleeding associated with uterine fibroids. Its clinical pipeline includes product candidates such as NBI-921352 and NBI-827104 for pediatric and focal epilepsy indications and essential tremor, as well as NBI-1065845, NBI-1065846, and NBI-118568 for major depressive disorder and schizophrenia.

Neurocrine expanded revenue from $1.13B in FY2021 to $2.86B in FY2025, representing a 5-year revenue CAGR of 22.3%. Gross margin remained consistently strong, registering at 98.2% in FY2025 compared to 98.7% in FY2021. Annual net income grew from $89.6M in FY2021 to $478.6M in FY2025, bringing diluted earnings per share to $6.40. R&D spending increased to $1.02B in FY2025 from $328.1M in FY2021. Over the trailing twelve months, revenue reached $3.37B with a net profit margin of 20.9% and an operating margin of 22.2%. In the quarter ended June 30, 2026, quarterly revenue increased 39.5% and quarterly earnings rose 31.1% year-over-year.

As of June 30, 2026, Neurocrine held $389.8M in cash and short-term investments against total debt of $401.8M, resulting in net debt of $12.0M. The company maintains a current ratio of 1.87 and a debt-to-equity ratio of 0.11 across $3.69B in shareholders' equity. In FY2025, operating cash flow stood at $782.7M, supporting capital expenditures of $34.0M and generating free cash flow of $748.7M. Capital allocation in FY2025 included $167.7M spent on share buybacks, while share count rose 9.8% over the trailing five-year period.

At a share price of $135.71 and a market cap of $13.79B, Neurocrine trades at a trailing P/E of 19.9x and a forward P/E of 14.1x. These multiples compare to 24.6x trailing and 17.3x forward P/E for the median of its US-listed Healthcare peers. Its EV/EBITDA of 15.7x sits above the peer median of 12.0x, while its price-to-sales multiple of 4.1x matches the peer median. Over the past year, NBIX shares fell 1.3%, trailing the S&P 500 return of 16.8%, and gained 29.8% over five years compared to 83.0% for the index.

Wall Street coverage includes 21 Strong Buy, 4 Buy, and 4 Hold ratings, with zero Sell recommendations. The mean price target of $206.81 implies 52.4% upside compared to the last close of $135.71. For FY2026, analysts estimate revenue of $3.90B and EPS of $10.19, reflecting projected EPS growth of 59.4%. For FY2027, 15 analysts project revenue of $4.56B and EPS of $11.95. Neurocrine has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings release is scheduled for November 2, 2026.

This page is an AI-written research summary of Neurocrine Biosciences, Inc. (NBIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NBIX income statement, NBIX balance sheet, NBIX key metrics, NBIX analyst forecast, NBIX chart. See the NBIX stock overview for the latest quote and news.